In addition, TCR-T cell therapy or CRISPR-Cas9 genome editing tools has a potential strategy for WT1-exprssing AML (Tawara et al., 2017; Chapuis et al., 2019; Ruggiero et al., 2022). Here, WT1 is linked to acute myeloid leukemia.